Literature DB >> 10026342

Chlamydia pneumoniae and atherosclerosis.

Y K Wong1, P J Gallagher, M E Ward.   

Abstract

OBJECTIVE: To review the literature for evidence that chronic infection with Chlamydia pneumoniae is associated with atherosclerosis and acute coronary syndromes. DATA SOURCES: MEDLINE and Institute of Science and Information bibliographic databases were searched at the end of September 1998. Indexing terms used were chlamydi*, heart, coronary, and atherosclerosis. Serological and pathological studies published as papers in any language since 1988 or abstracts since 1997 were selected. DATA EXTRACTION: It was assumed that chronic C pneumoniae infection is characterised by the presence of both specific IgG and IgA, and serological studies were examined for associations that fulfilled these criteria. Pathological studies were also reviewed for evidence that the presence of C pneumoniae in diseased vessels is associated with the severity and extent of atherosclerosis. DATA SYNTHESIS: The majority of serological studies have shown an association between C pneumoniae and atherosclerosis. However, the number of cases in studies that have reported a positive association when using strict criteria for chronic infection is similar to the number of cases in studies which found no association. Nevertheless, the organism is widely found in atherosclerotic vessels, although it may not be at all diseased sites and is not confined to the most severe lesions. Rabbit models and preliminary antibiotic trials suggest that the organism might exacerbate atherosclerosis.
CONCLUSION: More evidence is required before C pneumoniae can be accepted as playing a role in atherosclerosis. Although use of antibiotics in routine practice is not justified, large scale trials in progress will help to elucidate the role of C pneumoniae.

Entities:  

Mesh:

Year:  1999        PMID: 10026342      PMCID: PMC1728972          DOI: 10.1136/hrt.81.3.232

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  76 in total

1.  Chlamydia pneumoniae and acute myocardial infarction in Jerusalem.

Authors:  J D Kark; M Leinonen; O Paltiel; P Saikku
Journal:  Int J Epidemiol       Date:  1997-08       Impact factor: 7.196

2.  Induction of macrophage foam cell formation by Chlamydia pneumoniae.

Authors:  M V Kalayoglu; G I Byrne
Journal:  J Infect Dis       Date:  1998-03       Impact factor: 5.226

3.  Evidence of Chlamydia pneumoniae infection obtained by the polymerase chain reaction (PCR) in patients with acute myocardial infarction and coronary heart disease.

Authors:  B R Naidu; Y F Ngeow; P Kannan; R Jeyamalar; A Khir; K L Khoo; T Pang
Journal:  J Infect       Date:  1997-09       Impact factor: 6.072

4.  Chlamydia pneumoniae antibody titers are significantly associated with acute stroke and transient cerebral ischemia: the West Birmingham Stroke Project.

Authors:  P J Cook; D Honeybourne; G Y Lip; D G Beevers; R Wise; P Davies
Journal:  Stroke       Date:  1998-02       Impact factor: 7.914

5.  Humoral immune response to conserved epitopes of Chlamydia trachomatis and human 60-kDa heat-shock protein in women with pelvic inflammatory disease.

Authors:  M Domeika; K Domeika; J Paavonen; P A Mårdh; S S Witkin
Journal:  J Infect Dis       Date:  1998-03       Impact factor: 5.226

6.  Infection with Chlamydia pneumoniae accelerates the development of atherosclerosis and treatment with azithromycin prevents it in a rabbit model.

Authors:  J B Muhlestein; J L Anderson; E H Hammond; L Zhao; S Trehan; E P Schwobe; J F Carlquist
Journal:  Circulation       Date:  1998-02-24       Impact factor: 29.690

7.  Chlamydia pneumoniae antibody response in patients with acute myocardial infarction and their follow-up.

Authors:  S Mazzoli; N Tofani; A Fantini; F Semplici; F Bandini; A Salvi; R Vergassola
Journal:  Am Heart J       Date:  1998-01       Impact factor: 4.749

8.  The effect of prolonged doxycycline therapy on Chlamydia pneumoniae serological markers, coronary heart disease risk factors and forearm basal nitric oxide production.

Authors:  J Sinisalo; K Mattila; M S Nieminen; V Valtonen; M Syrjälä; S Sundberg; P Saikku
Journal:  J Antimicrob Chemother       Date:  1998-01       Impact factor: 5.790

9.  Chlamydia pneumoniae infection induces inflammatory changes in the aortas of rabbits.

Authors:  K Laitinen; A Laurila; L Pyhälä; M Leinonen; P Saikku
Journal:  Infect Immun       Date:  1997-11       Impact factor: 3.441

10.  Chlamydia pneumoniae, cytomegalovirus, and herpes simplex virus in atherosclerosis of the carotid artery.

Authors:  B Chiu; E Viira; W Tucker; I W Fong
Journal:  Circulation       Date:  1997-10-07       Impact factor: 29.690

View more
  15 in total

Review 1.  Vascular smooth muscle cell apoptosis in atherosclerosis.

Authors:  J J Boyle
Journal:  Int J Exp Pathol       Date:  1999-08       Impact factor: 1.925

2.  Comparison of two commercial microimmunofluorescence kits and an enzyme immunoassay kit for detection of serum immunoglobulin G antibodies to Chlamydia pneumoniae.

Authors:  T O Messmer; J Martinez; F Hassouna; E R Zell; W Harris; S Dowell; G M Carlone
Journal:  Clin Diagn Lab Immunol       Date:  2001-05

3.  Ultrastructural study of Chlamydia pneumoniae in a continuous-infection model.

Authors:  A Kutlin; C Flegg; D Stenzel; T Reznik; P M Roblin; S Mathews; P Timms; M R Hammerschlag
Journal:  J Clin Microbiol       Date:  2001-10       Impact factor: 5.948

4.  Ethnic distribution of Chlamydophila pneumoniae antibodies in a Malaysian population and possible correlation with coronary heart disease.

Authors:  Brindha R Naidu; Y F Ngeow; T Pang
Journal:  Eur J Epidemiol       Date:  2003       Impact factor: 8.082

5.  CD8+ T cells recognize an inclusion membrane-associated protein from the vacuolar pathogen Chlamydia trachomatis.

Authors:  S P Fling; R A Sutherland; L N Steele; B Hess; S E D'Orazio; J Maisonneuve; M F Lampe; P Probst; M N Starnbach
Journal:  Proc Natl Acad Sci U S A       Date:  2001-01-30       Impact factor: 11.205

6.  Analysis of the humoral immune response to Chlamydia pneumoniae by immunoblotting and immunoprecipitation.

Authors:  A Essig; U Simnacher; M Susa; R Marre
Journal:  Clin Diagn Lab Immunol       Date:  1999-11

7.  Chlamydia pneumoniae IgG titres and coronary heart disease: prospective study and meta-analysis.

Authors:  J Danesh; P Whincup; M Walker; L Lennon; A Thomson; P Appleby; Y Wong; M Bernardes-Silva; M Ward
Journal:  BMJ       Date:  2000-07-22

8.  Matrix metalloproteinase-9 expression is associated with the presence of Chlamydia pneumoniae in human coronary atherosclerotic plaques.

Authors:  G Arno; J C Kaski; D A Smith; J P Akiyu; S E Hughes; C Baboonian
Journal:  Heart       Date:  2005-04       Impact factor: 5.994

9.  Comparison of eleven commercial tests for Chlamydia pneumoniae-specific immunoglobulin G in asymptomatic healthy individuals.

Authors:  Corinna Hermann; Kathrin Graf; Annemarie Groh; Eberhard Straube; Thomas Hartung
Journal:  J Clin Microbiol       Date:  2002-05       Impact factor: 5.948

10.  Effect of prolonged treatment with azithromycin, clarithromycin, or levofloxacin on Chlamydia pneumoniae in a continuous-infection Model.

Authors:  Andrei Kutlin; Patricia M Roblin; Margaret R Hammerschlag
Journal:  Antimicrob Agents Chemother       Date:  2002-02       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.